BRAF and neoplasm: Conversely, the use of very sensitive molecular techniques, which could detect a minor BRAF-mutated subclone in a predominantly wild-type tumor, may not be clinically relevant as BRAF inhibitors may have opposite signaling effects in cells with mutated or wild-type BRAF [23].